4D Molecular Therapeutics, Inc. FDMT
14.47
(0.24)
(1.63%)
as of 25 Sep
- Market cap
- $807.1M
- P/E
- 0.0×
Follow FDMT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (43.25%) | (34.92%) | (27.57%) | (45.38%) |
+8 more TTM periods Free account |
|
| (37.09%) | (31.28%) | (24.86%) | (40.70%) | ||
ROIC |
(186.91%) | (184.13%) | (96.80%) | (225.26%) | |
Return on Tangible Assets |
(51.54%) | (42.84%) | (36.49%) | (71.78%) | |
Average Days of Receivables |
18.29 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.22) | (1.90) | (1.89) | (3.30) | |
Free Cash Flow |
(155.96) | (129.34) | (109.62) | (185.05) | |
Capital Expenditures |
0.11 | 0.11 | (0.54) | (1.55) | |
Piotroski F-Score |
2.00 | 2.00 | 3.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(19.79%) | (15.36%) | (12.01%) | (27.22%) | |
Accounts Receivable Turnover |
31.57 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
261.18% | 249.29% | 229.67% | 150,977.50% | |
Selling, General and Administrative Expense of Revenue |
53.06% | 54.18% | 57.58% | 41,105.00% | |
Share Based Compensation of Revenue |
22.18% | 22.08% | 25.84% | 20,034.17% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.87 | 0.80 | 0.78 | 0.88 | |
Depreciation/Fixed assets |
0.05 | 0.02 | 0.00 | (0.05) | |
Capex/Depreciation |
0.18 | 0.34 | 13.40 | 1.80 | |
Revenue per Share |
1.31 | 1.30 | 1.47 | 0.00 | |
Operating CF per Share |
(2.22) | (1.90) | (1.88) | (3.27) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.03) | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 12.96 | |
Net Profit Margin |
(194.74%) | (182.34%) | (164.43%) | (174,314.17%) |
Columns are period end dates